Main Menu

ICCG HMFEC trial

FE 50 C versus FE 75 C with or without sequential hormone therapy in women with node positive premenopausal breast cancer.

Disease site: Breast cancer

Treatment modality: Chemotherapy

Status: Closed

Trial details

International multicentre randomised study of adjuvant chemotherapy comparing efficacy and toxicity of ‘standard’ dose 5-fluorouracil, epirubicin and cyclophosphamide (FE 50 C) with a ‘higher’ dose 5-flouorouracil, epirubicin and cyclophosphamide (FE 75 C) and evaluating the additional benefit of sequential hormone therapy. 785 premenopausal women with node positive primary breast cancer from 7 countries were randomised to receive 8 cycles of FE 50 C or FE 75 C given at 3 weekly intervals with or without sequential hormone therapy. Depending on hormonal status at the end of chemotherapy patients randomised sequential therapy were prescribed either GnRH agonist for 3 years or tamoxifen for 5 years.

This is an International Collaborative Cancer Group (ICCG) trial (C/9/91).

Publications and presentations

Bliss J, Wils J, Marty M, Coombes G, Lawrence D, Coombes RC, on behalf of the ICCG. Evaluation of the tolerability of FE50C versus FE75C in a prospective randomised trial in adjuvant breast cancer patients. J. Clin. Oncol. 2002;20:15S #2017

Clinical trials

Division of Clinical Studies

The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.